Comparative Pharmacology
Head-to-head clinical analysis: BRISDELLE versus LUVOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISDELLE versus LUVOX.
BRISDELLE vs LUVOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.
Selective serotonin reuptake inhibitor (SSRI); increases serotonergic activity by blocking reuptake of serotonin into presynaptic neurons.
8 mg orally once daily, taken at bedtime.
Initial dose 50 mg orally once daily at bedtime, titrated by 50 mg increments every 4-7 days to effective dose; usual therapeutic range 100-300 mg/day divided once daily (at bedtime) or twice daily if tolerated. Maximum dose 300 mg/day.
None Documented
None Documented
Clinical Note
moderateFluvoxamine + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Fluvoxamine."
Clinical Note
moderateFluvoxamine + Desmopressin
"The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desmopressin."
Clinical Note
moderateFluvoxamine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Fluvoxamine."
Clinical Note
moderateFluvoxamine + Clotrimazole
Terminal elimination half-life is approximately 9-11 hours for paroxetine (the active ingredient in Brisdelle). This supports once-daily dosing; steady-state is achieved within 7-14 days.
The terminal elimination half-life is approximately 15-20 hours but may be prolonged in patients with hepatic impairment or with advanced age. Steady-state is typically achieved within 7-10 days of chronic dosing.
Primarily renal excretion as metabolites; approximately 60% of a radiolabeled dose is recovered in urine and 30% in feces over 10 days. Less than 1% excreted unchanged.
Approximately 94% of a dose is excreted in urine, mostly as conjugated and oxidized metabolites, with 2% as unchanged drug. Fecal excretion accounts for less than 4%.
Category C
Category C
SSRI Antidepressant
SSRI Antidepressant
"The metabolism of Clotrimazole can be decreased when combined with Fluvoxamine."